Constipation affects an estimated 15 percent of people worldwide and can significantly reduce quality of life, yet its underlying causes remain incompletely understood. New research suggests that, for many patients, constipation is not simply the result of slowed digestion but a complex disorder involving interactions between the gut, the immune system, and the nervous system.
One common subtype, slow-transit constipation, is characterized by delayed movement of stool through the intestines. Scientists have long suspected that abnormalities in the enteric nervous system—the extensive network of nerves embedded within the intestinal wall—play a central role. This system coordinates peristalsis, the rhythmic muscle contractions that move food waste through the digestive tract.
The Gut-Brain Axis Comes Into Focus
A recent paper published in Frontiers in Immunology proposes that chronic constipation may result from disruptions in the gut-brain axis. This bidirectional communication network connects intestinal microbes, immune responses, the intestinal barrier, and the enteric nervous system, sometimes referred to as the body’s “second brain.”
The researchers propose a conceptual model known as the Trigger–Gateway–Hub–Effector framework to organize current evidence. Their aim is to integrate findings from human studies, animal experiments, and laboratory research into a unified, testable model explaining how chronic constipation develops and persists.
According to the framework, the Trigger stage begins with alterations in the gut microbiota, known as dysbiosis. Diet, medications such as antibiotics or opioids, infections, and lifestyle factors can all alter the composition of intestinal microbes and change the metabolites they produce.
These microbial metabolites—including short-chain fatty acids, bile acid derivatives, inflammatory lipopolysaccharides, and tryptophan metabolites involved in serotonin signaling—act as molecular messengers. Some promote healthy intestinal function, whereas others may contribute to inflammation or impaired intestinal motility when present in abnormal amounts or combinations.
Leaky Barriers and Immune Communication
In the proposed model, the intestinal lining serves as the Gateway. This epithelial barrier allows nutrients and water to be absorbed while preventing harmful substances and microorganisms from entering the bloodstream. Mucus and tight junctions between intestinal cells work together to maintain this essential protective barrier.
The authors suggest that metabolites produced during dysbiosis may weaken the intestinal barrier, increasing its permeability. Although a more permeable, or “leaky,” intestine may not directly cause constipation, it may create conditions that make immune activation and nerve dysfunction more likely.
Once the barrier becomes compromised, microbial molecules may interact more readily with immune cells located within the intestinal wall. This interaction may trigger low-grade chronic inflammation similar to that observed in irritable bowel syndrome. The researchers emphasize that impaired barrier function is likely to amplify downstream biological processes rather than act as the sole cause of impaired intestinal motility.
Within the framework, the Hub represents the microenvironment surrounding the enteric nervous system. At this level, signals from neurons, glial cells that support nerve function, connective tissue cells, immune cells, and intestinal microbes are integrated. Even relatively subtle disturbances in this communication network may influence how intestinal muscles contract.
Enteric Nerves as the Final Effector
The Effector stage focuses on the enteric nervous system itself, where multiple biological pathways ultimately converge. Research suggests that chronic inflammation and abnormal signaling may contribute to the loss of nerve cells, alterations in neurotransmitter balance, or damage to specialized pacemaker cells responsible for coordinating intestinal muscle contractions.
These specialized cells, known as the interstitial cells of Cajal, are often described as the electrical pacemakers of the gastrointestinal tract because they generate the slow-wave activity that organizes peristalsis. Dysfunction of these cells has been observed in some patients with severe constipation, supporting the hypothesis that neuromuscular abnormalities underlie many difficult-to-treat cases.
The authors note that the current evidence linking changes in the gut microbiota to constipation remains moderate. Much of the available research comes from observational studies and experimental models rather than large mechanistic studies in humans. Nevertheless, findings from multiple lines of research increasingly support a multisystem explanation for chronic constipation.
The framework may also help explain why constipation frequently occurs alongside other disorders involving the gut-brain axis, including irritable bowel syndrome, functional dyspepsia, and certain mood disorders. Researchers increasingly suspect that these conditions may share overlapping biological pathways rather than representing entirely separate disorders.
Implications for Future Treatments
The proposed framework also has important implications for treatment. If constipation results from interconnected disturbances involving intestinal microbes, barrier integrity, immune responses, and nerve function, effective treatment may need to address several biological systems simultaneously. Conventional laxatives, which primarily improve stool consistency and intestinal transit, may not adequately treat all patients.
One promising strategy involves modifying the gut microbiota. Probiotics, prebiotics, and dietary interventions designed to increase fiber intake and promote short-chain fatty acid production are already used in clinical practice, although their effectiveness varies between individuals. More advanced approaches, including fecal microbiota transplantation, have shown encouraging results in related gastrointestinal disorders but remain experimental for constipation.
Another potential approach focuses on reducing chronic inflammation within the intestinal wall. This strategy could involve therapies targeting specific inflammatory pathways, although researchers note that any long-term treatment would need to balance effectiveness with safety, particularly in otherwise healthy individuals.
Protecting or restoring the function of enteric neurons and interstitial cells of Cajal may eventually represent a third therapeutic strategy. However, the authors emphasize that no clinically established neuroprotective treatments for chronic constipation currently exist, and additional basic research will be necessary to identify suitable therapeutic targets.
In the future, treatment may combine microbiota-directed therapies, immune modulation, and approaches that support intestinal nerve function alongside conventional laxatives and lifestyle measures such as regular exercise and adequate hydration. Personalized medicine approaches—including microbiome profiling and biomarker-guided treatment—may also help match patients with therapies most likely to benefit them.
The authors conclude that viewing constipation through the Trigger–Gateway–Hub–Effector framework could accelerate future research and improve the design of clinical trials. By clarifying how diverse biological risk factors converge on the enteric nervous system, they hope to advance treatment beyond symptom management toward therapies that address the underlying causes of chronic constipation.